Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Hiroaki Baba, Hajime Kanamori, Kengo Oshima, Issei Seike, Ikumi Niitsuma-Sugaya, Kentaro Takei, Yukio Sato, Koichi Tokuda, Tetsuji Aoyagi

研究成果: Article査読

4 被引用数 (Scopus)

抄録

We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

本文言語English
ページ(範囲)1100-1103
ページ数4
ジャーナルJournal of Infection and Chemotherapy
26
10
DOI
出版ステータスPublished - 2020 10

ASJC Scopus subject areas

  • 微生物学(医療)
  • 感染症
  • 薬理学(医学)

フィンガープリント

「Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル